Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

In vitro cytotoxicity of cabazitaxel in adrenocortical carcinoma cell lines and human adrenocortical carcinoma primary cell cultures.

Fragni M, Palma Lopez LP, Rossini E, Abate A, Cosentini D, Salvi V, Vezzoli S, Poliani PL, Bosisio D, Hantel C, Tiberio GAM, Grisanti S, Memo M, Terzolo M, Berruti A, Sigala S.

Mol Cell Endocrinol. 2019 Sep 16;498:110585. doi: 10.1016/j.mce.2019.110585. [Epub ahead of print]

PMID:
31536779
2.

Antineoplastic activity of artemisinin in adrenocortical carcinoma.

Lorini L, Grisanti S, Ambrosini R, Cosentini D, Laganà M, Grazioli L, Tiberio GAM, Sigala S, Berruti A.

Endocrine. 2019 Sep 6. doi: 10.1007/s12020-019-02077-7. [Epub ahead of print] No abstract available.

PMID:
31493273
3.

Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma.

Fiorentini C, Grisanti S, Cosentini D, Abate A, Rossini E, Berruti A, Sigala S.

J Oncol. 2019 Apr 1;2019:6072863. doi: 10.1155/2019/6072863. eCollection 2019. Review.

4.

Transformation of Prostate Adenocarcinoma Into Small-Cell Neuroendocrine Cancer Under Androgen Deprivation Therapy: Much Is Achieved But More Information Is Needed.

Volta AD, Cosentini D, Antonelli A, Pedersini R, Simeone C, Volante M, Berruti A.

J Clin Oncol. 2019 Feb 1;37(4):350-351. doi: 10.1200/JCO.18.01055. Epub 2018 Dec 17. No abstract available.

PMID:
30557524
5.

Eight-week interval in flushing and locking port-a-cath in cancer patients: A single-institution experience and systematic review.

Fornaro C, Piubeni M, Tovazzi V, Cosentini D, Gelmi M, Rota G, Berta B, Barucco W, Lombardi E, Moles L, Faustini T, Fettolini T, Motta P, Ferrari VD, Berruti A, Conti E.

Eur J Cancer Care (Engl). 2019 Mar;28(2):e12978. doi: 10.1111/ecc.12978. Epub 2018 Dec 10.

PMID:
30536872
6.

Immunotherapy failure in adrenocortical cancer: where next?

Cosentini D, Grisanti S, Dalla Volta A, Laganà M, Fiorentini C, Perotti P, Sigala S, Berruti A.

Endocr Connect. 2018 Nov 1. pii: EC-18-0398.R1. doi: 10.1530/EC-18-0398. [Epub ahead of print]

7.

Cost-effectiveness of model-based eligibility for lung cancer screening in the routine clinical practice.

Intagliata S, Roca E, Cosentini D, Berruti A.

Ann Transl Med. 2018 Sep;6(18):369. doi: 10.21037/atm.2018.07.24. No abstract available.

8.

In vitro antitumor activity of progesterone in human adrenocortical carcinoma.

Fragni M, Fiorentini C, Rossini E, Fisogni S, Vezzoli S, Bonini SA, Dalmiglio C, Grisanti S, Tiberio GAM, Claps M, Cosentini D, Salvi V, Bosisio D, Terzolo M, Missale C, Facchetti F, Memo M, Berruti A, Sigala S.

Endocrine. 2019 Mar;63(3):592-601. doi: 10.1007/s12020-018-1795-x. Epub 2018 Oct 26.

PMID:
30367443
9.

Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.

Puglisi S, Perotti P, Cosentini D, Roca E, Basile V, Berruti A, Terzolo M.

Expert Rev Anticancer Ther. 2018 Nov;18(11):1125-1133. doi: 10.1080/14737140.2018.1510325. Epub 2018 Aug 21. Review.

PMID:
30117750
10.

Hepatoprotective effect of N-acetylcysteine in trabectedin-induced liver toxicity in patients with advanced soft tissue sarcoma.

Grisanti S, Cosentini D, Tovazzi V, Bianchi S, Lazzari B, Consoli F, Roca E, Berruti A, Ferrari VD.

Support Care Cancer. 2018 Aug;26(8):2929-2935. doi: 10.1007/s00520-018-4129-x. Epub 2018 Mar 15.

PMID:
29546526

Supplemental Content

Loading ...
Support Center